Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer

doi:10.3969/j.issn.1006-7795.2023.01.021

Journal of Capital Medical University ›› 2023, Vol. 44 ›› Issue (1): 143-147.doi: 10.3969/j.issn.1006-7795.2023.01.021

• Clinical Research • Previous Articles Next Articles

Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer

Wang Wenwen¹, Cai Yu^1*, Jia Shuangshuang², Zhai Jianjun¹

1. Department of Obstetrics and Gynecology, Beijing Tongren Hospital, Capital Medical University,Beijing 100176, China;
2. Department of Pathology, Beijing Tongren Hospital, Capital Medical University,Beijing 100176, China

Received:2022-10-18 Online:2023-02-21 Published:2023-01-13
Contact: *E-mail: caiyu892002@sina.com
Supported by:
Hospital Founding of Beijing Tongren Hospital, Capital Medical University(2021YJJPY012), Undergraduate Scientific Research Innovation Project of Capital Medical University(XSKY2022).

Abstract

Abstract: Objective To investigate the relationship between kinesin family proteins 2C (KIF2C) and chemoresistance in ovarian cancer. Methods Totally 151 patients with epithelial ovarian cancer who underwent surgery in Beijing Tongren Hospital, Capital Medical University from January 2010 to December 2020 were selected. Among them, 98 patients were sensitive to platinum chemotherapy and 53 patients were resistant to platinum chemotherapy. The expression of KIF2C in chemosensitive and chemoresistant ovarian cancer was detected by immunohistochemistry. Results The expression of KIF2C was significantly lower in the chemoresistant tissues of ovarian cancer. KIF2C and pathological stage ⅢC are the risk factors of chemotherapy resistance in ovarian cancer. Conclusion KIF2C may become a marker for predicting the chemosensitivity of ovarian cancer patients and a new therapeutic target in resistant ovarian cancer.

Key words: chemotherapy resistance, ovarian cancer, kinesin family proteins 2C (KIF2C)

CLC Number:

R737.31

Wang Wenwen, Cai Yu, Jia Shuangshuang, Zhai Jianjun. Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer[J]. Journal of Capital Medical University, 2023, 44(1): 143-147.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.01.021

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I1/143

References

[1] Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics,2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[2] Christie E L, Bowtell D D L. Acquired chemotherapy resistance in ovarian cancer[J]. Ann Oncol, 2017, 28(Suppl 8): viii13－viii15.
[3] Chandra A, Pius C, Nabeel M, et al. Ovarian cancer: current status and strategies for improving therapeutic outcomes[J]. Cancer Med, 2019, 8(16): 7018-7031.
[4] Wang W W, Zhang W W, Hu Y J. Identification of keygenes, miRNAs and miRNA-mRNA regulatory pathways for chemotherapy resistance in ovarian cancer[J]. PeerJ, 2021, 9: e12353.
[5] Gan H Z, Lin L, Hu N J, et al. KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR-325-3p[J]. Cell Biochem Funct, 2019, 37(6): 424-431.
[6] Bie L, Zhao G, Wang Y P, et al. Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas[J]. Clin Neurol Neurosurg, 2012, 114(4): 356-360.
[7] Wei S, Dai M M, Zhang C, et al. KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma[J]. Protein Cell, 2021, 12(10): 788-809.
[8] Gnjatic S, Cao Y R, Reichelt U, et al. NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer[J]. Int J Cancer, 2010, 127(2): 381-393.
[9] Armstrong D K, Alvarez R D, Bakkum-Gamez J N, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(2): 191-226.
[10] Johnston S R D. Ovarian cancer: review of the National Institute for Clinical Excellence (Nice) guidance recommendations[J]. Cancer Invest, 2004, 22(5): 730-742.
[11] Banks J D, Heald R. Chromosome movement: dynein-out at the kinetochore[J]. Curr Biol, 2001, 11(4): R128-R131.
[12] Kinoshita K, Noetzel T L, Arnal I, et al. Global and local control of microtubule destabilization promoted by a catastrophe kinesin MCAK/XKCM1[J]. J Muscle Res Cell Motil, 2006, 27(2): 107-114.
[13] Xia P, Zhou J H, Song X Y, et al. Aurora A orchestrates entosis by regulating a dynamic MCAK-TIP150 interaction[J]. J Mol Cell Biol, 2014, 6(3): 240-254.
[14] Bendre S, Rondelet A, Hall C, et al. GTSE1 tunes microtubule stability for chromosome alignment and segregation by inhibiting the microtubule depolymeraseMCAK[J]. J Cell Biol, 2016, 215(5): 631-647.
[15] Yang J, Wu Z M, Yang L, et al. Characterization of kinesin family member 2C as a proto-oncogene in cervical cancer[J]. Front Pharmacol, 2022, 12: 785981.
[16] An L F, Zhang J, Feng D L, et al. KIF2C is a novel prognostic biomarker and correlated with immune infiltration in endometrial cancer[J]. Stem Cells Int, 2021, 2021: 1434856.
[17] Sanhaji M, Friel C T, Wordeman L, et al. Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target[J]. Oncotarget, 2011, 2(12): 935-947.
[18] Ganguly A, Yang H L, Cabral F. Overexpression of mitotic centromere-associated kinesin stimulates microtubule detachment and confers resistance to paclitaxel[J]. Mol Cancer Ther, 2011, 10(6): 929-937.
[19] Ganguly A, Yang H L, Pedroza M, et al. Mitotic centromere-associated kinesin (MCAK) mediates paclitaxel resistance[J]. J Biol Chem, 2011, 286(42): 36378-36384.
[20] Jiang C F, Xie Y X, Qian Y C, et al. TBX15/miR-152/KIF2C pathway regulates breast cancer doxorubicin resistance via promoting PKM2 ubiquitination[J]. Cancer Cell Int, 2021, 21(1): 542.

Relationship between kinesin family proteins 2C and chemoresistance in ovarian cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	Liu Qun, Li Lina, Liu Jian, Miao Jinwei. SOX4 mediates TGF-β1 induced epithelial-mesenchymal transition to promote invasion and metastasis of ovarian cancer [J]. Journal of Capital Medical University, 2022, 43(3): 336-342.
[2]	Zhang Zixin, Meng Ying, Liang Yuting. MR-NIRF Fe₃O₄-Cy5.5-NGR bimodel contrast agents ovarian cancer cells [J]. Journal of Capital Medical University, 2018, 39(1): 84-91.
[3]	Liu Chen, Wu Long, Jiang Hongchuan, Li Jie, Liu Jun, Wang Shuzhen. Risk factor of second primary gynecological malignancy among women with breast cancer surgery [J]. Journal of Capital Medical University, 2017, 38(1): 92-96.
[4]	Li Jinfeng;Zhang Zhenyu;Wang Shuzhen;Liu Jinwei. The Anti-tumor Immunity and Cultivation of the Fused Cells of Ovarian Cancer and Dendritic Cells Derived from Cord Blood——An In-vitro Study [J]. Journal of Capital Medical University, 2007, 28(5): 604-608.
[5]	Wei Wei;Shen Keng;Zhao Lihong;Cao Yang. Establishment of Fisher344 Rat Animal Model of Epithelial Ovarian Cancer [J]. Journal of Capital Medical University, 2007, 28(1): 52-55.
[6]	Lin Yugeng;Zhang Zhenyu;Wang Lisheng;Wu Bin. Effects of Wild-type p53,GM-CSF and B7-1 Genes Transfer on Proliferation of Ovarian Cancer Cell Line SKOV-3 [J]. Journal of Capital Medical University, 2005, 26(5): 588-592.